alexa Reduction In The Volume Of Water For Ingesting And The Clinical Disintegration Time Of Orally Disintegrating Tablets Of Solifenacin (Vesicare? OD)
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Summit on Clinical Pharmacy
December 02-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Shinya Uchida
ScientificTracks Abstracts: Clinic Pharmacol Biopharm
DOI: 10.4172/2167-065X.S1.006
Abstract
Orally disintegrating tablets (ODTs) disintegrate immediately in the mouth so that patients can take it without water. This characteristic of ODTs is beneficial for patients who have difficulty swallowing conventional tablets (CTs). Furthermore, ingestion of ODTs without water may be beneficial for patients with an overactive bladder (OAB) who have lower urinary tract symptoms and are thought to experience discomfort and inconvenience with water intake. Solifenacin (Vesicare?, VES) is an antimuscarinic agent for the management of OAB. This study aimed to determine the amount of water required for ingesting placebos of VES-ODT and of VES-CT. Healthy volunteers participated in this randomized crossover trial. The participants were asked to drink water during the intake VES-CT and after the disintegration of VES-ODT in their oral cavity. The amounts of water required for ingesting VES-CT and of VES-ODT were 42.8 mL and 20.0 mL, respectively, which indicated that the amount of water required for ingesting ODTs was significantly lesser than that for ingesting CTs. Furthermore, 5 (16.7%) participants did not require water for ingesting the ODTs. The amount of water required for taking 3 tablets was reduced with increasing the number of ODTs (1, 2 or 3 ODTs). Clinical disintegration time of VES-ODT was 21.4 sec in 10 healthy volunteers. This clinical disintegration time did not change significantly after unit-dose packaging or subsequent storage for 56 days. This study showed that the amount of water required for ingesting VES-ODT is lower than that for ingesting VES-CT.
Biography
Shinya Uchida, PhD, received his PhD degree from University of Shizuoka in 1999. He served as clinical pharmacist at University Hospital of Hamamatsu School of Medicine. He is Associate Professor at University of Shizuoka and his major interests include clinical pharmaceutical science, clinical pharmacology and pharmacokinetics. He has published more than 50 papers in reputed journals.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords